DDInter1702 DDInter1867
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Thioridazine
Thioridazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) downregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is upregulated by {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) upregulates {v} (Gene) NPC1
NPC1 {u} (Gene) is upregulated by {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) downregulates {v} (Gene) UBE2C
UBE2C {u} (Gene) is downregulated by {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Triflupromazine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Perphenazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Thioridazine
Thioridazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Sorafenib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Triflupromazine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Triflupromazine (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Triflupromazine (Compound)
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Triflupromazine (Compound)
Sorafenib (Compound) downregulates SLC2A6 (Gene) and SLC2A6 (Gene) is upregulated by Triflupromazine (Compound)
Sorafenib (Compound) upregulates NPC1 (Gene) and NPC1 (Gene) is upregulated by Triflupromazine (Compound)
Sorafenib (Compound) downregulates UBE2C (Gene) and UBE2C (Gene) is downregulated by Triflupromazine (Compound)
Sorafenib (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Triflupromazine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Triflupromazine (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Triflupromazine (Compound)
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Desipramine (Compound) and Desipramine (Compound) resembles Triflupromazine (Compound)